Glenmark gets tentative US nod for migraine treatment drug

Glenmark Pharma's US generics arm has received tentative approval from US Food and Drugs Administration (FDA) for Zolmitriptan orally disintegrating tablets, its copy of AstraZeneca's ZomigZMT tablets.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
Real-time Stock quotes, portfolio, LIVE TV and more.
GeStepAhead SME Special
moneycontrol.com

Home » News » Business

May 16, 2012, 08.44 PM | Source: Moneycontrol.com

Glenmark gets tentative US nod for migraine treatment drug

Glenmark Pharma's US generics arm has received tentative approval from US Food and Drugs Administration (FDA) for Zolmitriptan orally disintegrating tablets, its copy of AstraZeneca's ZomigZMT tablets.

Like this story, share it with millions of investors on M3

Glenmark gets tentative US nod for migraine treatment drug

Glenmark Pharma's US generics arm has received tentative approval from US Food and Drugs Administration (FDA) for Zolmitriptan orally disintegrating tablets, its copy of AstraZeneca's ZomigZMT tablets.

Post Your Comments

Share Cancel

Moneycontrol Bureau

Glenmark Pharma 's US generics arm has received tentative approval from US Food and Drugs Administration (FDA) for Zolmitriptan orally disintegrating tablets, its copy of AstraZeneca's ZomigZMT tablets.

The drug is used to treat acute migraine attacks. The tentative approval for the 2.5 mg and 5 mg Zolmitriptan orally disintegrating tablets is one of the first granted by the US drug regulator a for a generic version of this medicine, it said.

Glenmark was granted tentative approval for immediate release version of Zolmitriptan tablets in September last year. It plans to launch the product in May 2013, upon getting final approval from the US FDA.

For the year ended March 2012, Zolmitriptan immediate release tablets, and orally disintegrating tablets had sales of USD 131 million and USD 31 million respectively, Glenmark said, citing IMS Health data.

It currently has 80 products authorized for distribution in the US and 38 ANDAs (abbreviated new drug application) pending approval with the US FDA.
 
Glenmark shares were down 2.8% at Rs 354.85 on NSE in noon trade.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Glenmark gets tentative US nod for migraine treatment drug

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login